Share on LinkedInShare on LinkedIn

ARTICLE · 08 MAY 2018

Tribal Sovereign Immunity Alone Cannot Protect Patents From IPR

In late March, the Federal Circuit issued an order staying the PTAB proceedings concerning numerous related IPRs of patents issued to Allergan, Inc. ("Allergan") ...

United StatesIntellectual Property

In late March, the Federal Circuit issued an order staying the PTAB proceedings concerning numerous related IPRs of patents issued to Allergan, Inc. ("Allergan"), but assigned to the Saint Regis Mohawk Tribe ("the Tribe"). These IPRs were headed toward a final hearing on the merits previously scheduled for April 3rd. In those IPRs, the PTAB denied the Tribe's motions to terminate the proceedings based upon the Tribe's sovereign immunity. Mylan Pharma Inc. v. Saint Regis Mohawk Tribe, Case IPR2016-01127, Paper 130 (February 23, 2018). This post explains the PTAB's decision that the court will now review on appeal. On December 8, 2016, the Board had instituted IPR proceedings for the Allergan Restasis® patents in response to petitions filed by Mylan Pharmaceuticals, Inc. ("Mylan") and various later-joined Petitioners Less than a week before final hearing, counsel for the Tribe informed the Board that the Tribe had acquired the challenged patents from Allergan. The Tribe

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from